Download PDF
Thromb Haemost 2017; 117(12): 2291-2299
DOI: 10.1160/TH17-03-0198
Coagulation and Fibrinolysis
Schattauer GmbH Stuttgart

Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries

Anders Nissen Bonde
,
Gregory Y. H. Lip
,
Anne-Lise Kamper
,
Laila Staerk
,
Christian Torp-Pedersen
,
Gunnar Gislason
,
Jonas Bjerring Olesen
Further Information

Publication History

21 March 2017

20 August 2017

Publication Date:
06 December 2017 (online)

    Permissions and Reprints

Abstract

Patients with severely reduced renal function have been excluded from randomized controlled trials of oral anticoagulation in atrial fibrillation (AF). Warfarin treatment in this population is controversial and data on anticoagulation control and the impact on adverse outcomes are needed. By individual-level linkage of nationwide registries, we identified all patients discharged from hospitals with AF in Denmark between 1997 and 2011. Patients with available serum creatinine tests were categorized according to the estimated glomerular filtration rate (eGFR). Time in therapeutic range (TTR) was calculated using the Rosendaal method. The risk of stroke and bleeding was estimated using multivariable Cox regression analyses with eGFR and TTR estimated time dependently throughout follow-up. We identified 10,423 warfarin-treated AF patients with available international normalized ratio and creatinine tests; 5,527 with eGFR > 60 mL/min/1.73 m2, 4,524 with eGFR 30–60 mL/min/1.73 m2 and 372 with eGFR < 30 mL/min/1.73 m2. Median TTR was 66.7, 61.2 and 49.7% in patients with eGFR > 60, 30–59 and <30 mL/min/1.73 m2, respectively. A TTR < 70% was associated with a higher risk of stroke/thromboembolism (hazard ratio [HR]: 1.39; 95% confidence interval [CI]: 1.20–1.60) and bleeding (HR: 1.22; 95% CI: 1.05–1.42) among patients with eGFR of 30 to 59 and a trend towards higher risk of stroke/thromboembolism (HR: 1.24; 95% CI: 0.86–1.80) and bleeding (HR: 1.17; 95% CI: 0.83–1.65) among patients with eGFR < 30 mL/min/1.73 m2. In conclusion, warfarin-treated AF patients with reduced renal function have suboptimal anticoagulation control which was related to the risk of adverse outcomes.

Keywords

atrial fibrillation - chronic kidney disease - warfarin - time in therapeutic range

The review process for this paper was fully handled by Christian Weber, Editor in Chief.


Supplementary Material

 

  • References

  • 1 Go AS, Fang MC, Udaltsova N. , et al; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119 (10) 1363-1369
    CrossrefPubMedGoogle Scholar
  • 2 Bonde AN, Lip GYH, Kamper A-L. , et al. Renal function and the risk of stroke and bleeding in patients with atrial fibrillation: an observational cohort study. Stroke 2016; 47 (11) 2707-2713
    CrossrefPubMedGoogle Scholar
  • 3 Olesen JB, Lip GY, Kamper AL. , et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367 (07) 625-635
    CrossrefPubMedGoogle Scholar
  • 4 Jun M, James MT, Manns BJ. , et al; Alberta Kidney Disease Network. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ 2015; 350: h246
    CrossrefPubMedGoogle Scholar
  • 5 Limdi MA, Crowley MR, Beasley TM, Limdi NA, Allon M. Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study. Am J Kidney Dis 2013; 61 (02) 354-357
    CrossrefPubMedGoogle Scholar
  • 6 Connolly SJ, Ezekowitz MD, Yusuf S. , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 7 Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013; 29 (7, Suppl): S71-S78
    CrossrefPubMedGoogle Scholar
  • 8 Bonde AN, Lip GY, Kamper AL. , et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014; 64 (23) 2471-2482
    CrossrefPubMedGoogle Scholar
  • 9 Carrero JJ, Evans M, Szummer K. , et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 2014; 311 (09) 919-928
    CrossrefPubMedGoogle Scholar
  • 10 Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20 (10) 2223-2233
    CrossrefPubMedGoogle Scholar
  • 11 Shah M, Avgil Tsadok M, Jackevicius CA. , et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014; 129 (11) 1196-1203
    CrossrefPubMedGoogle Scholar
  • 12 Wizemann V, Tong L, Satayathum S. , et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77 (12) 1098-1106
    CrossrefPubMedGoogle Scholar
  • 13 Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011; 6 (11) 2662-2668
    CrossrefPubMedGoogle Scholar
  • 14 Friberg L, Benson L, Lip GYH. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36 (05) 297-306
    CrossrefPubMedGoogle Scholar
  • 15 White HD, Gruber M, Feyzi J. , et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167 (03) 239-245
    CrossrefPubMedGoogle Scholar
  • 16 Connolly SJ, Pogue J, Eikelboom J. , et al; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118 (20) 2029-2037
    CrossrefPubMedGoogle Scholar
  • 17 Björck F, Renlund H, Lip GY, Wester P, Svensson PJ, Själander A. Outcomes in a warfarin-treated population with atrial fibrillation. JAMA Cardiol 2016; 1 (02) 172-180
    CrossrefPubMedGoogle Scholar
  • 18 Bonde AN, Lip GY, Kamper A-L. , et al. Effect of reduced renal function on time in therapeutic range among anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2017; 69 (06) 752-753
    PubMedGoogle Scholar
  • 19 Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46 (03) 263-268
    PubMedGoogle Scholar
  • 20 Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39 (7, Suppl): 30-33
    CrossrefPubMedGoogle Scholar
  • 21 Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44 (04) 445-448
    PubMedGoogle Scholar
  • 22 Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39 (7, Suppl): 38-41
    CrossrefPubMedGoogle Scholar
  • 23 Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39 (7, Suppl): 22-25
    CrossrefPubMedGoogle Scholar
  • 24 Hommel K, Rasmussen S, Madsen M, Kamper AL. The Danish Registry on Regular Dialysis and Transplantation: completeness and validity of incident patient registration. Nephrol Dial Transplant 2010; 25 (03) 947-951
    CrossrefPubMedGoogle Scholar
  • 25 De Caterina R, Camm AJ. What is ‘valvular’ atrial fibrillation? A reappraisal. Eur Heart J 2014; 35 (47) 3328-3335
    CrossrefPubMedGoogle Scholar
  • 26 Sørensen R, Hansen ML, Abildstrom SZ. , et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374 (9706): 1967-1974
    CrossrefPubMedGoogle Scholar
  • 27 Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69 (03) 236-239
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Kirchhof P, Benussi S, Kotecha D. , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18 (11) 1609-1678
    CrossrefPubMedGoogle Scholar
  • 29 Olesen JB, Lip GY, Hansen ML. , et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124
    CrossrefPubMedGoogle Scholar
  • 30 Olesen JB, Lip GY, Hansen PR. , et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011; 9 (08) 1460-1467
    CrossrefPubMedGoogle Scholar
  • 31 Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J 2011; 162 (03) 548-554
    CrossrefPubMedGoogle Scholar
  • 32 Levey AS, Stevens LA, Schmid CH. , et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150 (09) 604-612
    CrossrefPubMedGoogle Scholar
  • 33 Herzog CA, Asinger RW, Berger AK. , et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80 (06) 572-586
    CrossrefPubMedGoogle Scholar
  • 34 Limdi NA, Nolin TD, Booth SL. , et al. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis 2015; 65 (05) 701-709
    CrossrefPubMedGoogle Scholar
  • 35 Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001; 12 (02) 326-332
    PubMedGoogle Scholar
  • 36 Dreisbach AW, Japa S, Gebrekal AB. , et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 2003; 73 (05) 475-477
    PubMedGoogle Scholar
  • 37 Limdi NA, Limdi MA, Cavallari L. , et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010; 56 (05) 823-831
    CrossrefPubMedGoogle Scholar
  • 38 Juma S, Thomson BK, Lok CE, Clase CM, Blake PG, Moist L. Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty. BMC Nephrol 2013; 14: 174
    CrossrefPubMedGoogle Scholar
  • 39 Kooiman J, van Rein N, Spaans B. , et al. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. PLoS One 2014; 9 (05) e94420
    CrossrefPubMedGoogle Scholar
  • 40 Limdi NA, Beasley TM, Baird MF. , et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20 (04) 912-921
    CrossrefPubMedGoogle Scholar
  • 41 Szummer K, Gasparini A, Eliasson S. , et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc 2017; 6 (03) e004926
    PubMedGoogle Scholar
  • 42 Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011; 32 (18) 2282-2289
    CrossrefPubMedGoogle Scholar
  • 43 Wallentin L, Yusuf S, Ezekowitz MD. , et al; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376 (9745): 975-983
    CrossrefPubMedGoogle Scholar
  • 44 Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007; 28 (03) 150-154
    CrossrefPubMedGoogle Scholar
  • 45 Sundbøll J, Adelborg K, Munch T. , et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open 2016; 6 (11) e012832
    CrossrefPubMedGoogle Scholar